Filgrastim, used to prevent febrile neutropenia (FN) in patients undergoing chemotherapy, is the first drug in the United States to have a biosimilar approved. While the biosimilar filgrastim was approved in 2015, few studies have compared the real-world incidence of FN, healthcare resource utilization, and costs among US patients using the reference product (Neupogen) and those using the approved biosimilar (Zarxio).
Filgrastim, used to prevent febrile neutropenia (FN) in patients undergoing chemotherapy, is the first drug in the United States to have a biosimilar approved. Since its 2015 approval, few studies have compared the real-world incidence of FN, healthcare resource utilization, and costs among US patients using the reference product (Neupogen) and among those using the approved biosimilar (Zarxio).
A new study, published in the Journal of Managed Care & Specialty Pharmacy, reports on a retrospective claims analysis of patients with nonmyeloid cancer who were enrolled in commercial or Medicare Advantage plans between 2015 and 2016, and who received either the reference or the biosimilar filgrastim during their first observed chemotherapy cycle.
The research team, led by Lee Schwartzberg, MD, used the Optum Research Database to identify patients 18 years or older who had at least 1 claim for filgrastim following the first cycle of chemotherapy. A total of 3542 patients met inclusion criteria, of whom 172 received the biosimilar and 3370 received the reference filgrastim. Weighted cohorts were created using inverse probability of treatment weighting to arrive at a 162-patient biosimilar cohort and a 3297-patient reference cohort.
The researchers found that the incidence of FN between the weighted treatment cohorts was statistically equivalent (90% CI of the difference of percentages was within ±6%), as well as the following:
With respect to costs, the researchers found the following:
Considering the high cost of FN and the potential for prophylaxis with filgrastim to save on costs, say the authors, underutilization of the reference and biosimilar filgrastim has serious consequences in terms of healthcare costs.
“Given that [the biosimilar] is less costly than [the reference]…increasing use of the biosimilar has the potential to promote guideline compliance by improving drug access,” write the authors. “This scenario has already been borne out in Europe, where burgeoning acceptance of biosimilar filgrastim since its 2008 approval has led to more widespread use of prophylaxis, suggesting that health care providers are more able and/or willing to follow clinical guidelines now that the biosimilar is available.”
Reference
Schartzberg LS, Lal LS, Balu S, et al. Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia—associated costs among patients with nonmyeloid cancer undergoing chemotherapy [published online April 24, 2018]. J Manag Care Spec Pharm. doi: 10.18553/jmcp.2018.17447.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.